Introduction {#S0001}
============

Overactive bladder (OAB) is characterized by urinary urgency, which is usually accompanied by frequency and nocturia, with or without urinary incontinence \[[1](#CIT0001)\]. Symptoms experienced by patients with OAB can profoundly and negatively affect many aspects of health-related quality of life (HRQoL), including psychological, social, occupational, and sexual function \[[2](#CIT0002)\]. Individuals with OAB report significantly lower HRQoL scores compared with matched controls, indicating impaired overall health \[[2](#CIT0002)\].

OAB is a common condition and its prevalence increases with age \[[3](#CIT0003)\]. The overall global prevalence of OAB was 10.7% (455 million cases) in 2008, and a 20.1% increase is predicted by 2018 (546 million cases) \[[4](#CIT0004)\]. The associated costs of OAB are substantial. An economic model estimated that the annual cost of OAB to the UK healthcare system was approximately €1 billion (2005 values), with an additional €579 million required for nursing home stays and €233 million for lost productivity due to work absenteeism \[[5](#CIT0005)\].

In the UK, the National Institute for Health and Care Excellence (NICE) recommends conservative management (e.g., bladder training and lifestyle advice) as initial treatment for OAB or storage lower urinary tract symptoms, followed by pharmacotherapy with antimuscarinic agents \[[6](#CIT0006),[7](#CIT0007)\] or the β~3~-adrenoceptor agonist, mirabegron \[[7](#CIT0007)\]. Several antimuscarinics are approved for treating OAB, including older generation (e.g., oxybutynin and trospium chloride) and newer generation (e.g., solifenacin, tolterodine, and fesoterodine) agents.

Solifenacin is a competitive muscarinic M~3~-receptor antagonist available as an oral once-daily tablet at two dosage strengths \[[8](#CIT0008)\]. The efficacy of solifenacin 5 and 10 mg (fixed doses) and 5 mg/10 mg (flexible dosing schedule) has been comprehensively studied in a series of large randomized controlled trials (RCTs) in patients with OAB \[[9](#CIT0009)--[12](#CIT0012)\]. These show that solifenacin is significantly more effective than placebo \[[9](#CIT0009),[10](#CIT0010)\], and provides greater efficacy than tolterodine for most outcomes \[[9](#CIT0009),[11](#CIT0011),[12](#CIT0012)\]. The most commonly reported adverse events (AEs) with solifenacin are dry mouth and constipation \[[9](#CIT0009),[10](#CIT0010)\].

OAB is a chronic condition and long-term use of pharmacotherapy may be required to control symptoms. Although many cost-effectiveness analyses of antimuscarinic agents in OAB have been performed, most compare only two agents over a short time-frame based on available data from RCTs and therefore provide only limited economic data to guide clinical decision-makers. By applying data from a recent network meta-analysis (NMA) \[[13](#CIT0013)\] to a Markov model for OAB \[[14](#CIT0014),[15](#CIT0015)\], we constructed a single analysis to evaluate the long-term (5-year) cost-effectiveness of solifenacin 5 mg/day compared with several other oral antimuscarinics routinely prescribed for adults with OAB from a UK National Health Service (NHS) perspective.

Materials and methods {#S0002}
=====================

Model overview {#S0002-S2001}
--------------

Markov modelling is a decision-tree method frequently used to evaluate the cost-effectiveness of medicines, where the disease or treatment process is represented by a series of health states. Markov models assume that a patient is always in one of a finite number of discrete health states (e.g., severity of symptoms) and the effect of treatment is represented as transitions between states \[[16](#CIT0016)\]. The models are set to a clinically relevant time horizon, divided into equal segments (i.e., cycles); during each cycle, patients have a defined probability of remaining in the same state or transitioning between states. Each health state is associated with a specific cost and utility value (i.e., relative preference scores between different health states on a scale of 0 \[worst imaginable health\] to 1 \[full/perfect health\]). Cumulative costs and quality-adjusted life years (QALYs; i.e., health-related benefit gained) for each treatment at the designated time horizon are calculated.

Model description {#S0002-S2002}
-----------------

A prior Markov model was developed to simulate the therapeutic management and disease course in a hypothetical cohort of adults with OAB \[[14](#CIT0014),[15](#CIT0015)\]. The model was adapted to predict the costs and QALYs gained from treatment with solifenacin 5 mg/day versus other oral antimuscarinics. The base-case scenario included a 1-month cycle and a 5-year time horizon. The model was programmed in Microsoft® Excel 2010. Costs and outcomes were discounted at a rate of 3.5% per year \[[17](#CIT0017)\], which converts future expected values to current values.

The model and assumptions applied were described previously in detail \[[14](#CIT0014),[15](#CIT0015)\]. The model simulates changes in key OAB symptoms (i.e., number of micturitions and incontinence episodes per day), transitions between treatments (i.e., initial treatment, next-line treatment, off-treatment, and botulinum toxin type A \[BTX-A\]); and occurrence of AEs (i.e., dry mouth and constipation). Different antimuscarinic agents are characterized by their effects on symptoms, likelihood of AEs, and acquisition costs.

At model entry, patients were assigned to either oral solifenacin 5 mg/day or a comparator antimuscarinic agent (Figure S1). For the primary analysis, the comparator was tolterodine extended-release (ER) 4 mg/day; for the secondary analyses, the comparators were fesoterodine 4 or 8 mg/day, oxybutynin ER or immediate-release (IR) 10 mg/day, solifenacin 10 mg/day, tolterodine IR 4 mg/day, or trospium chloride 60 mg/day. BTX-A (injection into the detrusor muscle) was an option for patients who failed treatment with ≥2 antimuscarinics.

Model inputs {#S0002-S2003}
------------

### Key data sources {#S0002-S2003-S3001}

Data for solifenacin 5 mg/day were derived from 905-CL-015, an international, multicenter, double-blind, controlled trial that randomized patients (n = 1081) to 12 weeks' treatment with solifenacin 5 or 10 mg/day, tolterodine 4 mg/day, or placebo \[[10](#CIT0010)\]. Solifenacin (5 and 10 mg/day) was reported as significantly more effective than placebo in decreasing the frequency of urgency, urgency urinary incontinence, all incontinence and micturition episodes over 24 hours. There was no formal statistical testing of solifenacin versus tolterodine.

In the absence of direct head-to-head trials, NMAs are an extension of traditional meta-analyses and allow multiple pairwise comparisons across interventions \[[18](#CIT0018)\]. We conducted a Bayesian NMA to estimate the relative efficacy and tolerability of solifenacin 5 mg/day versus other oral antimuscarinics in patients with OAB \[[13](#CIT0013)\]. The NMA included 53 RCTs, identified from a systematic literature search performed in 2015 \[[13](#CIT0013)\]; the NMA data used in our model are presented in Table S1.

### Symptom severity {#S0002-S2003-S3002}

Micturition frequency and incontinence had five severity levels in the model. The initial distribution of patients in each symptom severity stratum was based on pooled baseline data from trial 905-CL-015 (Table S2). From months 0 to 3, monthly transition probabilities between symptom levels for solifenacin 5 mg/day were estimated by applying a multinomial regression model to the 905-CL-015 data (Table S3). Transition probabilities after Month 3 were assumed to be the same as between Months 2 and 3, based on evidence from two long-term studies which suggested that the treatment effect of antimuscarinic agents at 3 or 4 months is sustained up to 24 months \[[19](#CIT0019),[20](#CIT0020)\]. For other antimuscarinics, transition probabilities were derived from the NMA results using a calibration approach \[[21](#CIT0021)\], which aimed to minimize the difference between changes in symptom severity predicted from the model and changes estimated from the NMA. Transition probabilities for next-line therapies were assumed to be the same as for tolterodine. After treatment discontinuation, patient distribution by symptom severity was assumed to be similar to baseline.

### Adverse events {#S0002-S2003-S3003}

The probabilities of dry mouth and constipation for solifenacin 5 mg/day were derived from 905-CL-015 \[[10](#CIT0010),[22](#CIT0022)\]. For other antimuscarinics, odds ratios from the NMA \[[13](#CIT0013)\] (Table S1) were used to adjust the probability of each AE ([Table 1](#T0001)).10.1080/20016689.2018.1438721-T0001Table 1.Model inputs for adverse events, treatment pathways, and utilities.ParameterBase-case valueDeterministic sensitivity analysis valuesSource**Adverse events, %^a^**   Dry mouth    Solifenacin 5 mg14.310.2--18.4Astellas \[[22](#CIT0022)\] Tolterodine ER 4 mg14.912.8--17.8Nazir et al. \[[13](#CIT0013)\] Fesoterodine 4 mg15.112.2--19.3Nazir et al. \[[13](#CIT0013)\] Fesoterodine 8 mg28.924.8--33.7Nazir et al. \[[13](#CIT0013)\] Oxybutynin ER 10 mg21.016.3--27.2Nazir et al. \[[13](#CIT0013)\] Oxybutynin IR 10 mg37.126.4‒51.0Nazir et al. \[[13](#CIT0013)\] Solifenacin 10 mg27.524.3--30.9Nazir et al. \[[13](#CIT0013)\] Tolterodine IR 4 mg22.318.1--25.7Nazir et al. \[[13](#CIT0013)\] Trospium chloride 60 mg12.77.7‒18.5Nazir et al. \[[13](#CIT0013)\]Constipation    Solifenacin 5 mg7.24.2--10.2Chapple et al. \[[10](#CIT0010)\] Tolterodine ER 4 mg4.33.0--6.2Nazir et al. \[[13](#CIT0013)\] Fesoterodine 4 mg3.72.4--5.8Nazir et al. \[[13](#CIT0013)\] Fesoterodine 8 mg6.94.8‒10Nazir et al. \[[13](#CIT0013)\] Oxybutynin ER 10 mg3.71.7--7.5Nazir et al. \[[13](#CIT0013)\] Oxybutynin IR 10 mg3.72.1--6.4Nazir et al. \[[13](#CIT0013)\] Solifenacin 10 mg12.29.9--15Nazir et al. \[[13](#CIT0013)\] Tolterodine IR 4 mg3.71.7--7.5Nazir et al. \[[13](#CIT0013)\] Trospium chloride 60 mg15.18.1‒27.7Nazir et al. \[[13](#CIT0013)\]**Treatment pathways**   Monthly probability of treatment discontinuation, %    Without adverse events    Solifenacin 5 mg/day6.83.4--10.2Calculated from Chapple et al. \[[24](#CIT0024)\] and Castro-Diaz et al. \[[23](#CIT0023)\] Other antimuscarinics6.83.4--10.2Assumption With adverse events90.050.0--100.0AssumptionMonthly probability of treatment switch after discontinuation, %26.16.7--39.1Odeyemi et al. \[[25](#CIT0025)\];^b^ assumptionMonthly probability of treatment restart, %5.60--8.42Assumption^c^Monthly probability of BTX-A injection, %0.10--0.05AssumptionProbability of reinjection after 6 months, %70.050.0--100.0Assumption**Utilities^d^**   Micturition  Aballéa et al. \[[14](#CIT0014)\] Level 10.06320.0453--0.0811  Level 20.04220.0258--0.0587  Level 30.02040.0045--0.0363  Level 40.0104--0.0316 Incontinence  Aballéa et al. \[[14](#CIT0014)\] Level 10.05860.0422--0.0749  Level 20.04370.0271--0.0602  Level 30.03140.0142--0.0486  Level 40.0128--0.0369 Decrement for adverse events--0.03570 to -- 0.1Aballéa et al. \[[14](#CIT0014)\][^2][^3]

### Treatment discontinuation, switch and restart {#S0002-S2003-S3004}

For the base-case analysis, the discontinuation rate was disaggregated according to whether patients withdrew because of AEs (i.e., dry mouth or constipation) or other reasons (i.e., lack of efficacy or other) ([Table 1](#T0001)). The probability of discontinuation due to AEs was assumed to be 90% as no published data were available for this parameter. The probability of discontinuation for other reasons (6.8%) was estimated from the literature \[[23](#CIT0023),[24](#CIT0024)\]. The probability of treatment switch after discontinuation (26.1%) was taken from a UK study \[[25](#CIT0025)\], and the probability of restarting treatment among patients who discontinued treatment without immediate treatment switch was assumed in the absence of published data (5.6%).

### Botulinum toxin type A {#S0002-S2003-S3005}

The probability of receiving BTX-A and treatment success with BTX-A were assumed in the absence of published data ([Table 1](#T0001)). If BTX-A treatment was successful, it was assumed that injections were repeated 6-monthly, whereas patients who failed BTX-A were assumed to receive no further treatment.

### Health-state utilities {#S0002-S2003-S3006}

Health-state utility values according to symptom severity were derived from EuroQol five dimensions questionnaire (EQ-5D) index scores, a generic HRQoL instrument, reported in the SCORPIO trial \[[26](#CIT0026)\], using a UK time trade-off tariff \[[27](#CIT0027)\]. A linear regression model was used to estimate EQ-5D utilities by symptom severity ([Table 1](#T0001)), adjusting for independent variables of patient sex, age and country (Table S4). A utility decrement for AEs was also estimated based on repeated regression analysis of the EQ-5D data ([Table 1](#T0001)); this was applied for the duration of a cycle for patients who experienced AEs and stayed on-treatment.

### Costs and resource utilization {#S0002-S2003-S3007}

Costs and resources were considered from a UK NHS perspective ([Table 2](#T0002)) \[[28](#CIT0028)--[31](#CIT0031)\]. Direct medical costs and resources considered in the model were: *antimuscarinic drug acquisition costs*: patients were assumed to use 1 tablet/day until discontinuation (drug wastage and partial compliance were not considered); *primary care and specialist consultations*: visits were assumed at baseline and upon initiation of a new medication; *specialist consultations*: 1.5 outpatient urologist visits were assumed upon initiation of new medication \[[32](#CIT0032)\]; *incontinence pads*: mean number of pads/day was based on incontinence severity level and estimated using data from 905-CL-015 \[[33](#CIT0033)\]; and *BTX-A injections*: acquisition and administration costs \[[28](#CIT0028)--[30](#CIT0030)\]. Costs were presented in pounds sterling (2015--2016 values).10.1080/20016689.2018.1438721-T0002Table 2.Model inputs for resource use and costs.ParameterBase-case valueDeterministic sensitivity analysis valuesSource**Resource use**   Pad utilization, number per month^a^  Astellas \[[33](#CIT0033)\] Level 16.975.83--8.10  Level 223.4820.80--26.16  Level 344.4739.76--49.18  Level 458.1352.10--64.15  Level 5121.30111.88--130.72 GP consultations1 visit at treatment initiation and BTX-A;0‒2AssumptionSpecialist consultations1 visit at treatment initiation and BTX-A;0‒2Assumption**Costs**   Monthly acquisition costs    Solifenacin 5 mg£28.00‒BNF \[[28](#CIT0028)\] Tolterodine ER 4 mg£28.01‒BNF \[[28](#CIT0028)\] Fesoterodine 4 mg£28.01‒BNF \[[28](#CIT0028)\] Fesoterodine 8 mg£28.01‒BNF \[[28](#CIT0028)\] Oxybutynin ER 10 mg£27.92‒BNF \[[28](#CIT0028)\] Oxybutynin IR 10 mg£2.40‒BNF \[[28](#CIT0028)\] Solifenacin 10 mg£36.41‒BNF \[[28](#CIT0028)\] Tolterodine IR 4 mg£2.88‒BNF \[[28](#CIT0028)\] Trospium chloride 60 mg£25.04‒BNF \[[28](#CIT0028)\]GP consultation (first visit)£65.00‒Curtis & Burns \[[29](#CIT0029)\]GP consultation (follow-up)£27.00‒Curtis & Burns \[[29](#CIT0029)\]Specialist visit (first visit or follow-up)£94.00‒Department of Health \[[30](#CIT0030)\]BTX-A injection/reinjection£1,151.98^b^‒BNF \[[28](#CIT0028)\]; Curtis & Burns \[[29](#CIT0029)\]; Department of Health \[[30](#CIT0030)\]Incontinence pad£0.17‒AgeUK incontinence \[[31](#CIT0031)\][^4]

Model outputs {#S0002-S2004}
-------------

Cost-effectiveness was estimated by calculating the relative differences in total costs and QALYs for solifenacin 5 mg/day versus another antimuscarinic over the model time horizon to yield an incremental cost-effectiveness ratio (ICER), expressed as cost per QALY gained.$$ICER\, = \,\frac{Cost\,\, difference\,\,(solifenacin\,\, 5\, mg/day\, - \, comparator\,\, antimuscarinic)}{QALY\,\, difference\,(solifenacin\,\, 5\, mg/day\, - \, comparator\,\, antimuscarinic)}$$

A willingness-to-pay (WTP) threshold of £30,000 per QALY gained was used to interpret the ICERs in this study. A maximum acceptable ICER threshold of £20,000--£30,000 per QALY gained is generally used to determine the probability that a treatment is cost effective in the UK \[[17](#CIT0017)\], but reports suggest that some decisions appear to have been based on a threshold higher than £20,000--£30,000 per QALY gained \[[34](#CIT0034)\].

Sensitivity and scenario analyses {#S0002-S2005}
---------------------------------

Model inputs are subject to uncertainty; therefore, the stability of the base-case results were tested using deterministic and probabilistic sensitivity analyses. For the deterministic sensitivity analysis, model parameters were varied independently over a plausible range of values determined either by using the 95% confidence intervals around the point estimate or a sensible range of values where there was no sampling uncertainty ([Table 1](#T0001)). Data were depicted in Tornado diagrams. For the probabilistic sensitivity analysis, input variables with uncertainties were varied simultaneously according to predefined statistical distributions (data not shown). One thousand iterations with different sets of inputs drawn randomly from the statistical distributions were depicted in a cost-effectiveness plane, and the probability that solifenacin 5 mg/day was cost effective at different WTP thresholds was shown in a cost-effectiveness acceptability curve. A scenario analysis, in which discontinuation rates for each antimuscarinic agent were derived from a recent UK observational study \[[24](#CIT0024)\] (Table S5), was also performed; discontinuation rates are assumed to be identical for patients with and without AEs as data on AEs were not available.

Results {#S0003}
=======

Base-case analysis {#S0003-S2001}
------------------

The results of the primary and secondary base-case analyses over a 5-year period are presented ([Table 3](#T0003)). For the primary analysis, total costs per patient were lower with solifenacin 5 mg/day than tolterodine ER 4 mg/day (difference £23), and the solifenacin strategy was associated with a QALY gain (0.0066 QALYs). Solifenacin 5 mg/day was the dominant (i.e., more effective and less costly) treatment strategy versus tolterodine ER 4 mg/day.10.1080/20016689.2018.1438721-T0003Table 3.Cost-effectiveness analysis of solifenacin 5 mg/day compared with other oral antimuscarinic agents at 5 years (base-case scenario). Primary analysisSecondary analysis Solifenacin 5 mg/dayTolterodine ER 4 mg/dayFesoterodine 4 mg/dayFesoterodine 8 mg/dayOxybutynin ER 10 mg/dayOxybutynin IR 10 mg/daySolifenacin 10 mg/dayTolterodine IR 4 mg/dayTrospium chloride 60 mg/dayCost, £          Drug acquisition2672802832052491625025211 Other OAB drug(s)359355354376363381380365367 GP visits206204204212207213213208209 Specialist visits446443443459450463462451453 Botulinum toxin136134133145138147147139140 Incontinence pads320339331339330334327340322Total costs, £1,7331,7561,7481,7361,7371,5541,7781,5281,702Total QALYs3.7323.7253.7273.7233.7283.7243.7283.7233.730Incremental costs, £‒--23‒15‒3‒5179‒4620531Incremental QALYs‒0.00660.00430.00890.00330.00800.00410.00850.0020ICER, £ per QALY gained‒DominantDominantDominantDominant22,393Dominant23,97515,007[^5]

In the secondary analysis, solifenacin 5 mg/day was also dominant versus fesoterodine 4 and 8 mg/day, oxybutynin ER 10 mg/day, and solifenacin 10 mg/day. Solifenacin 5 mg/day was also cost-effective versus oxybutynin IR 10 mg/day (ICER, £22,393 per QALY), tolterodine IR 4 mg/day (ICER, £23,975 per QALY) and trospium chloride 60 mg/day (ICER, £15,007 per QALY).

Sensitivity analyses {#S0003-S2002}
--------------------

### Deterministic sensitivity analyses {#S0003-S2002-S3001}

Tornado diagrams for costs and QALYs for solifenacin 5 mg/day versus tolterodine ER 4 mg/day are shown in [Figure 1](#F0001). The model was generally most sensitive to the probability of treatment discontinuation, transition probabilities between symptom severity levels, the baseline distribution of patients across severity levels and the probability of dry mouth.10.1080/20016689.2018.1438721-F0001Figure 1.Deterministic sensitivity analysis: Tornado diagram showing the effects of varying key input parameters on (**A**) costs and (**B**) QALYs for solifenacin 5 mg/day versus tolterodine ER 4 mg/day.AE, adverse event; BTX-A, botulinum toxin type A; discon, discontinuation; ER, extended release; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year; prob, probability; soli, solifenacin; tolt, tolterodine; Tx, treatment; w/o, without; 2L, second-line.

### Probabilistic sensitivity analyses {#S0003-S2002-S3002}

The model was robust to simultaneous variations of model inputs. The cost-effectiveness plane and cost-effectiveness acceptability curve for solifenacin 5 mg/day versus tolterodine ER 4 mg/day are shown in [Figure 2](#F0002). At a WTP threshold of £30,000/QALY, the probability that solifenacin 5 mg/day was cost-effective versus tolterodine ER 4 mg/day was 93.3%, and versus other comparators was 94.2% (fesoterodine 4 mg/day), 98.3% (fesoterodine 8 mg/day), 86.6% (oxybutynin ER 10 mg/day), 66.8% (oxybutynin IR 10 mg/day), 93.3% (solifenacin 10 mg/day), 58.1% (tolterodine IR 4 mg/day), and 56.6% (trospium chloride 60 mg/day).10.1080/20016689.2018.1438721-F0002Figure 2.Probabilistic sensitivity analysis: (**A**) cost-effectiveness plane and (**B**) cost-effectiveness acceptability curve for solifenacin 5 mg/day versus tolterodine ER 4 mg/day.ER, extended-release; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.

### Scenario analysis {#S0003-S2002-S3003}

When discontinuation rates from a UK observational study were used as model inputs \[[24](#CIT0024)\], the results were generally similar to the base-case analysis except that solifenacin 5 mg/day was cost-effective, rather than dominant, versus oxybutynin ER (ICER, £156 per QALY), and solifenacin 5 mg/day was less costly and less effective (ICER, £39,731.60 per QALY) rather than dominant, versus solifenacin 10 mg/day (Table S5).

Discussion {#S0004}
==========

This economic model shows that, over a 5-year time horizon, solifenacin 5 mg/day is dominant (i.e., lower costs combined with a health benefit) versus tolterodine ER 4 mg/day, fesoterodine 4 and 8 mg/day, oxybutynin ER 10 mg/day and solifenacin 10 mg/day, and cost-effective versus oxybutynin IR 10 mg/day, tolterodine IR 4 mg/day and trospium chloride 60 mg/day for the treatment of adults with OAB from a UK payer perspective. The ICERs for all comparators were below the upper limit of the WTP range generally applied by NICE in their health technology appraisals (£20,000--£30,000 per QALY) \[[17](#CIT0017)\]. The probabilistic sensitivity analysis showed that, at a threshold of £30,000 per QALY, the probability of solifenacin 5 mg/day being cost effective exceeded 80% compared with fesoterodine 4 and 8 mg/day, tolterodine ER 4 mg/day, oxybutynin ER 4 mg/day and solifenacin 10 mg/day.

In our model, the results of the comparison with tolterodine ER 4 mg/day was driven primarily by differences in efficacy leading to QALY gains with solifenacin 5 mg/day, whereas for other comparators, the QALY gains and cost offsets were driven mainly by differences in AEs and persistence on treatment. Hence, the assumption that AEs are a key contributor to treatment discontinuation had an important role in our model. This assumption is supported by the literature, which shows that the most common reasons for discontinuing antimuscarinics are that treatment did not work as expected and side effects \[[35](#CIT0035)\]. Further, better persistence rates with solifenacin compared with other commonly prescribed antimuscarinics have been observed in routine clinical practice in the UK and are consistent with our model predictions \[[24](#CIT0024),[36](#CIT0036)\]. Given the key role played by discontinuation rates in our model, we replaced the assumed/derived values used in the base-case analysis with rates reported in a large UK observational study \[[24](#CIT0024)\]. The results were largely unchanged compared with the base-case analysis, except that solifenacin 5 mg/day was cost-effective versus oxybutynin ER and solifenacin 10 mg/day rather than dominant.

Three other cost-effectiveness analyses have compared solifenacin with oral antimuscarinics in adults with OAB from a UK healthcare provider perspective with 1-year time horizons; one used a decision-tree analysis \[[32](#CIT0032)\] and the other two \[[37](#CIT0037),[38](#CIT0038)\] were based on an earlier Markov model \[[39](#CIT0039)\]. In the decision-tree analysis \[[32](#CIT0032)\], solifenacin 5/10 mg/day was found to be dominant compared with tolterodine ER 4 mg/day and fesoterodine 4/8 mg/day. Similarly, a flexible dosing schedule of solifenacin 5/10 mg/day was also dominant compared with tolterodine ER 4 mg/day \[[38](#CIT0038)\]. In the third analysis, solifenacin 5/10 mg had an ICER of £12,309 compared with oxybutynin IR 15 mg/day \[[37](#CIT0037)\], although AEs were not considered in this model. These studies support our own and suggest that solifenacin 5 mg/day, whether given as a fixed- or flexible-dose schedule, is a dominant treatment strategy in cost-effectiveness terms compared with tolterodine ER 4 mg/day in the UK.

A strength of our analysis is that it compared solifenacin with antimuscarinics or formulations not considered in previous analyses. It is based on a new Markov state-transition model \[[14](#CIT0014),[15](#CIT0015)\], which was then adapted for the present study. Mirabegron, another pertinent comparator, has been considered in other previously reported analyses based on the same model \[[14](#CIT0014),[15](#CIT0015),[40](#CIT0040)\]. Unlike previous models described above, this model had a longer time horizon of 5 years, included treatment switching and treatment restart, as well as considering the effects of AEs on persistence and utilities. As OAB is known to be a chronic disorder with persistent symptoms \[[41](#CIT0041)\], our model goes some way to simulating the expected long-term outcomes and costs arising from this condition. Another strength of our model is that the utilities were based on the EQ-5D, the instrument preferred by NICE for cost-utility analyses \[[42](#CIT0042)\], and were estimated using data from a large trial of OAB patients. This cost-effectiveness analysis focuses on clinical practice in the UK and the results are potentially relevant in other countries because of consistency between OAB treatment guidelines, although we acknowledge that variations in healthcare practice may affect direct costs and the cost-effectiveness of specific interventions.

Limitations of our model included the use of indirect evidence from an NMA to estimate the relative efficacy and tolerability of solifenacin versus other antimuscarinics. Transition probabilities for comparators were determined by calibration, which led to uncertainty around these inputs. We also acknowledge that the model treatment pathway may have been over-simplified, e.g., solifenacin 10 mg/day was evaluated as an alternative to solifenacin 5 mg/day, but in reality is likely to be used as part of a flexible-dose schedule with solifenacin 5 mg/day. The model considered micturition and incontinence as symptoms of OAB, but excluded urgency and nocturia. The instruments used to measure urgency are subjective and have different severity thresholds, which would have introduced further uncertainty. Nocturia is multifactorial and not always related to OAB alone, so it was considered appropriate to omit both symptoms from the model.

Current NICE guidelines for urinary incontinence in women recommend oxybutynin IR, tolterodine IR and darifenacin as initial treatments followed by another drug with a low acquisition cost if the first treatment is either not effective or poorly tolerated \[[7](#CIT0007)\]. In our analysis, solifenacin 5 mg/day was cost-effective compared with oxybutynin IR and tolterodine IR (ICER £22,000 and £24,000 per QALY gained, respectively). We were unable to include darifenacin in the present model because it was not possible to estimate its relative effectiveness for incontinence. Our model emphasizes that drug acquisition cost is only one of several costs accrued when treating patients, and can be offset by treatment benefits, such as symptomatic and HRQoL improvements.

Conclusions {#S0005}
===========

Solifenacin 5 mg/day appears to be a cost-effective strategy compared with other oral antimuscarinic agents commonly used for the treatment of adults with OAB from a UK NHS perspective. By providing a comparative assessment of the cost effectiveness of oral antimuscarinic agents commonly used in the UK, these findings will help to inform decisions made by both clinicians and healthcare policy makers regarding treatment options for OAB.
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[^3]: ^a^Probability at 3 months. ^b^Based on switching among patients on tolterodine. ^c^A monthly probability of 5.6% (50% annually) was assumed for restarting treatment among patients who discontinued treatment without immediately switching to another drug. It was assumed that one-third of these patients would go back to their previous treatment, and one-third each would receive next line A and next line B. ^d^Coefficients for symptom severity level relative to symptom level 5, e.g. the utility of patients at micturition severity level 1 is higher than the utility of patients with micturition severity level 5 by 0.0632.

[^4]: BTX-A, botulinum toxin type A; ER, extended release; GP, general practitioner; IR, immediate release.

    ^a^According to incontinence symptom severity level. ^b^Botox® Allergan 100 unit vial + intermediate endoscopic bladder procedure + nurse review.

[^5]: ER, extended release; GP general practitioner; ICER, incremental cost-effectiveness ratio; IR, immediate release; OAB, overactive bladder; QALY, quality-adjusted life year.
